Current pharmaceutical biotechnology最新文献

Self-emulsifying drug delivery systems (SEDDS) can increase the solubility and bioavailability of poorly soluble drugs. The inability of 35% to 40% of new pharmaceuticals to dissolve in water presents a serious challenge for the pharmaceutical industry. As a result, there must be dosage proportionality, considerable intra- and inter-subject variability, poor solubility, and limited lung bioavailability. As a result, it is critical that drugs intended for oral administration be highly soluble. This can be improved through a variety of means, including salt generation and the facilitation of solid and complicated dispersion. Surfactants, lubricants, and cosolvents may occasionally be found in SEDDS or isotropic blends. Lipophilic drugs, whose absorption is limited by their dissolution rate, have been used to demonstrate the effectiveness of various formulations and techniques. These particles can form microemulsions and suitable oil-inwater emulsions with minimal agitation and dilution by the water phase as they pass through the gastrointestinal tract. This study summarises the numerous advances, biopharmaceutical components, variations, production techniques, characterisation approaches, limitations, and opportunities for SEDDS. With this context in mind, this review compiles a current account of biopharmaceutical advancements, such as the application of quality by design (QbD) methodologies to optimise drug formulations in different excipients with controllable ratios, the presence of regulatory roadblocks to progress, and the future consequences of SEDDS, encompassing composition, evaluation, diverse dosage forms, and innovative techniques for in vitro converting liquid SEDDS to solid forms.

Pain and swelling in the joints, increased synovial thickness, and bone and cartilage degeneration are all symptoms of Rheumatoid Arthritis (RA). Anti-rheumatic medications, which are used in conventional treatment plans for RA, need high doses, frequent administration, and long-term use, all of which increase the risk of major adverse effects and low patient compliance. Drug Delivery Systems (DDS) have been developed for RA treatment in an effort to avoid these obstacles and improve clinical efficacy. There have been many successful experimental RA models using these techniques. There has been a notable uptick in the study of RA nanotherapies as a prospective improvement over conventional systemic therapy. In order to overcome the limits of traditional treatments, researchers have begun looking into nanotherapeutic approaches, notably drug-delivery nanosystems. The precise delivery and concentration of therapeutic drugs in the affected regions are made possible by the passive or active targeting of systemic administration. Several new DDS for treating RA have been addressed here. Therefore, nanoscale drug delivery devices increase drug solubility and bioavailability while decreasing the need for higher doses.

One of the most common malignancies in women, breast cancer accounts for nearly 25% of all cancer cases. Breast cancer is a diverse cancer form that exhibits variability in both morphology and molecular characteristics, and is linked to numerous risk factors. Although various approaches and research are ongoing in the treatment and prevention of breast cancer, medication resistance in the current breast cancer treatment contributes to the disease's relapse and recurrence. Phytoactive molecules are the subject of growing research in both breast cancer prevention and treatment but currently used conventional medicines and techniques limit their application. Recent years have seen significant advancements in the field of nanotechnology, which has proven to be essential in the fight against drug resistance. The transport of synthetic and natural anticancer molecules via nanocarriers has recently been added to breast cancer therapy, greatly alleviating the constraints of the current approach. In light of these developments, interest in nano-delivery studies of phytoactive molecules has also increased. In this review, research of phytoactive molecules for breast cancers along with their clinical studies and nanoformulations, was presented from current and future perspectives.

Background: Atherosclerosis (AS) is a chronic inflammatory disease characterized by the accumulation of lipids, the formation of lesion plaques, and the narrowing of arterial lumens. Rhubarb has significant effects against AS, but there is a lack of analysis and exploration of the mechanism of action of the transitional components in serum containing rhubarb.

Objective: This work aims to combine serum pharmacochemistry, network pharmacology, and molecular docking to explore active ingredients and mechanism of rhubarb against AS.

Method: Firstly, the components of rhubarb in blood samples were identified using HPLC-QTOF/MS. The ingredients-targets-disease interaction network of rhubarb was constructed through network pharmacology. Then, molecular docking between the ingredients and the core targets was carried out using the Autodock Vina software.

Results: Eleven active ingredients and five metabolites were preliminarily identified. The network pharmacology results showed that chrysophanol, resveratrol, and emodin might have potential pharmacological effects on AS. The PPI network showed that the key proteins were PTGS2, ESR1, PTGS1, and ELANE. GO analysis revealed that genes were mainly enriched in the inflammatory response and response to exogenous stimuli. Moreover, these genes were related to IL-17 signaling pathways, lipid and atherosclerosis, and other pathways. Molecular docking analyses showed that chrysophanol and emodin have strong binding affinities with the target proteins PTGS2 and PTGS1.

Conclusion: A comprehensive strategy combining serum pharmacochemistry with network pharmacology and molecular docking was employed to investigate the active ingredients and the mechanism of rhubarb in treating AS, which provided a basis for studying the pharmacological effects and action mechanisms of rhubarb.

Early cancer identification is essential for increasing survival rates and lowering the disease's burden in today's society. Artificial intelligence [AI]--based algorithms may help in the early detection of cancer and resolve problems with current diagnostic methods. This article gives an overview of the prospective uses of AI in early cancer detection. The authors go over the possible applications of Artificial Intelligence algorithms used for screening risk of malignancy in asymptomatic patients, investigating as well as prioritising symptomatic individuals, and more accurately diagnosing cancer recurrence. In screening programmes, the importance of patient selection and risk stratification is emphasised, and AI may be able to assist in identifying people who are most at risk of acquiring cancer. Aside from pathology slide and peripheral blood analysis, AI can also increase the diagnostic precision of imaging methods like computed tomography [CT] and mammography. A summary of various AI techniques is given in the review, covering more sophisticated deep learning and neural networks and more traditional models like logistic regression. The advantages of deep learning algorithms in spotting intricate patterns in huge datasets and their potential to increase the precision of cancer diagnosis are emphasised by the authors. The ethical concerns surrounding the application of AI in healthcare are also discussed, and include topics like prejudice, data security, and privacy. A review of the models now employed in clinical practice is included along with a discussion of the prospective clinical implications of AI algorithms. Examined are AI's drawbacks and hazards, such as resource requirements, data quality, and the necessity for consistent reporting. In conclusion, this study emphasises the utility of AI algorithms in the early detection of cancer and gives a general overview of the many strategies and difficulties involved in putting them into use in clinical settings.

Background: Methicillin-resistant Staphylococcus aureus (MRSA) is a potential threat globally since it is associated with high morbidity and mortality. In addition, the ability of MRSA to develop resistance and adapt to various environments makes it exceptional from other bacterial strains. Effective management is best determined by the site of infection.

Objectives: This study aims to summarize and assess the epidemiology of MRSA, resistance, detection of MRSA in humans, animals, and food products, treatment employed, and combination therapy.

Methods: For the present review, we collected data from PubMed, Embase, Web of Science, BioMed Central, Medline, Encyclopedia of Life Sciences, Scopus, Cochrane Library, and ScienceDirect that report the epidemiology of MRSA, drug resistance in MRSA, spread of MRSA infection, diagnosis of infection, existing and emerging remedies of MRSA infections. Collected data were analyzed and represented in this article with the help of Figures and Tables.

Results: S. aureus resistance to vancomycin is because of genetic adaptation and also due to the widespread and indiscriminate use of antibiotics in the treatment of MRSA infection. Specifically, infections related to vancomycin-resistant S. aureus are life-threatening and difficult to treat. MRSA epidemiology with the recognition of community-acquired-MRSA transmission between livestock and humans is also reported and is alarming. Multiple studies suggested that early detection of MRSA colonization and elimination of carriage can help reduce the risk of subsequent infection. Specifically, PCR-based screening from different body sites offers the highest overall sensitivity for the detection of MRSA carriage.

Conclusion: Screening novel mutants and methods of transmission in each environment will assist in managing MRSA. Further, effective MRSA control in all clinical setups is required with the avoidance of uncontrolled antibiotic usage.

Motor neuron disorders are diseases that can be passed through generations by heredity or they occur due to spontaneous mutations in the gene. These are the disorders that weaken the connection between motor neurons and the muscles, due to this the coordination between the neurons and muscles gets disturbed and thereby the actions become abnormal, every year millions of people around the world suffer from these different types of motor neuron disorders. Till now there is no proper known treatment for this type of disorder, there is active research work going on to treat these diseases permanently. Some gene therapy treatments are giving promising results in the treatment of these diseases, specifically, genetic modification techniques are the front liners, and many types of nucleases are doing their work to replace the mutated gene with a functional one. Zinc finger nucleases (ZFNs) are one of them with good disease treatment potential with accurate and desirable effects. In this review, we note the complete information about ZFNs and their drawbacks along with their future prospective in gene therapy and also shortly with other types of nucleases-mediated gene therapies. There also some factors that influence the gene therapy treatment are also noted along with some detailed information.

Introduction: Commercial plastics are potentially hazardous and can be carcinogenic due to the incorporation of chemical additives along with other additional components utilized as brominated flame retardants and phthalate plasticizers during production that excessively produce large numbers of gases, litter, and toxic components resulting in environmental pollution.

Method: Biodegradable plastic derived from natural renewable resources is the novel, alternative, and innovative approach considered to be potentially safe as a substitute for traditional synthetic plastic as they decompose easily without causing any harm to the ecosystem and natural habitat. The utilization of undervalued compounds, such as by-products of fruits and vegetables in the production of biodegradable packaging films, is currently a matter of interest because of their accessibility, affordability, ample supply, nontoxicity, physiochemical and nutritional properties. Industrial food waste was processed under controlled conditions with appropriate plasticizers to extract polymeric materials. Biodegradability, solubility, and air test analysis were performed to examine the physical properties of polymers prior to the characterization of the biofilm by Fourier-transformed infrared spectroscopy (FTIR) for the determination of polymeric characteristics.

Result: The loss of mass examined in each bioplastic film was in the range of 0.01g to 0.20g. The dimension of each bioplastic was recorded in the range of 4.6 mm to 28.7 mm. The existence of -OH, C=C, C=O stretching, and other crucial functional groups that aid in the creation of a solid polymeric material are confirmed by FTIR analysis. This study provides an alternative approach for sustainable and commercially value-added production of polymeric-based biomaterials from agro-industrial waste as they are rich in starch, cellulose, and pectin for the development of bio-plastics.

Conclusion: The rationale of this project is to achieve a straightforward, economical, and durable method for the production of bio-plastics through effective utilization of industrial and commercial fruit waste, ultimately aiding in revenue generation.